WallStreetZenWallStreetZen

NASDAQ: CERE
Cerevel Therapeutics Holdings Inc Stock Forecast, Predictions & Price Target

Analyst price target for CERE

Based on 7 analysts offering 12 month price targets for Cerevel Therapeutics Holdings Inc.
Min Forecast
$45.00+9.76%
Avg Forecast
$45.00+9.76%
Max Forecast
$45.00+9.76%

Should I buy or sell CERE stock?

Based on 7 analysts offering ratings for Cerevel Therapeutics Holdings Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
7 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CERE stock forecasts and price targets.

CERE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-16
lockedlocked$00.00+00.00%2023-12-28
lockedlocked$00.00+00.00%2023-12-22
lockedlocked$00.00+00.00%2023-12-08
lockedlocked$00.00+00.00%2023-12-07
Piper Sandler
Top 24%
77
HoldDowngrades$45.00+9.76%2023-12-07
Cantor Fitzgerald
Top 6%
95
HoldDowngrades$45.00+9.76%2023-12-07

1 of 1

Forecast return on equity

Is CERE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.79%

Forecast return on assets

Is CERE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CERE revenue forecast

What is CERE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$13.5M
Avg 2 year Forecast
$19.5M
Avg 3 year Forecast
$94.2M

CERE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CERE$41.00$45.00+9.76%Hold
PCVX$68.70$96.00+39.74%Strong Buy
ASND$127.33$186.00+46.08%Strong Buy
LEGN$41.68$78.38+88.04%Strong Buy
VKTX$65.36$112.38+71.93%Strong Buy

Cerevel Therapeutics Holdings Stock Forecast FAQ

Is Cerevel Therapeutics Holdings Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: CERE) stock is to Hold CERE stock.

Out of 7 analysts, 0 (0%) are recommending CERE as a Strong Buy, 0 (0%) are recommending CERE as a Buy, 7 (100%) are recommending CERE as a Hold, 0 (0%) are recommending CERE as a Sell, and 0 (0%) are recommending CERE as a Strong Sell.

If you're new to stock investing, here's how to buy Cerevel Therapeutics Holdings stock.

What is CERE's revenue growth forecast for 2025-2027?

(NASDAQ: CERE) Cerevel Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.58%.

Cerevel Therapeutics Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CERE's revenue for 2025 to be $2,463,272,641, with the lowest CERE revenue forecast at $2,463,272,641, and the highest CERE revenue forecast at $2,463,272,641. On average, 1 Wall Street analysts forecast CERE's revenue for 2026 to be $3,552,797,079, with the lowest CERE revenue forecast at $3,552,797,079, and the highest CERE revenue forecast at $3,552,797,079.

In 2027, CERE is forecast to generate $17,162,742,812 in revenue, with the lowest revenue forecast at $17,162,742,812 and the highest revenue forecast at $17,162,742,812.

What is CERE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CERE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CERE's Price Target?

According to 7 Wall Street analysts that have issued a 1 year CERE price target, the average CERE price target is $45.00, with the highest CERE stock price forecast at $45.00 and the lowest CERE stock price forecast at $45.00.

On average, Wall Street analysts predict that Cerevel Therapeutics Holdings's share price could reach $45.00 by Feb 16, 2025. The average Cerevel Therapeutics Holdings stock price prediction forecasts a potential upside of 9.76% from the current CERE share price of $41.00.

What is CERE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CERE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.